Position in EXEL
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$14,826,178
+$432,040 QoQ
Shares Held
272,490
-18.8% QoQ
Ownership
0.110%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#110
of 751 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Empowered Funds, LLC holds $300,617,707 across 58 Biotechnology names. EXEL ranks #7 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
187,271 | $49,948,919 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
106,854 | $25,748,605 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
50,197 | $24,934,353 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
33,963 | $21,177,286 | |
| 5 | INCY |
Incyte Corp
|
174,884 | $19,824,845 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
223,142 | $17,692,927 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
272,490 | $14,826,178 | |
| 8 | ANAB |
Anaptysbio, Inc
|
206,010 | $13,905,675 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,826,178 | 272,490 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $14,394,138 | 335,606 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $10,687,460 | 243,839 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $10,244,587 | 248,053 | Shares | Other | 2025-11-13 | |
| 2025-06-30 | $18,836,528 | 427,326 | Shares | Other | 2025-08-11 | |
| 2025-03-31 | $11,172,102 | 302,603 | Shares | Other | 2025-05-16 | |
| 2024-12-31 | $7,455,170 | 223,879 | Shares | Other | 2025-01-28 | |
| No filing history on record for this holder in this stock. | ||||||